Dr. Gadgeel on Updated KEYNOTE-189 Data in NSCLC

Video

In Partnership With:

Shirish M. Gadgeel, MD, MBBS, professor, University of Michigan Medicine, discusses the updated results of the phase III KEYNOTE-189 trial in metastatic nonsquamous non-small cell lung cancer (NSCLC).

Shirish M. Gadgeel, MD, MBBS, professor, University of Michigan Medicine, discusses the updated results of the phase III KEYNOTE-189 trial in metastatic nonsquamous non—small cell lung cancer (NSCLC).

In the KEYNOTE-189 trial, patients were randomized to receive pembrolizumab (Keytruda) and chemotherapy versus chemotherapy alone. The median overall survival rate of patients with pembrolizumab added to chemotherapy was 22 months compared with 10.9 months for patients with chemotherapy alone.

At 2 years, 45.5% of patients who received pembrolizumab were alive compared with 29% of patients who received chemotherapy alone, showing a 16.5% improvement in survival with pembrolizumab. Progression-free survival was 9 months with pembrolizumab compared with 5 months for chemotherapy alone. These improvements were observed across all PD-L1 subsets, including patients whose tumor proportion score was 0. No additional safety signals were identified in this study, according to Gadgeel.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD